Conclusions Ezetimibe monotherapy ( 10 mg/day ) showed a small ( 7.06 % ) but statistically significant reduction in the plasma levels of Lp(a ) in patients with primary hypercholesterolemia .
According to current literature , this magnitude of reduction seems to have no clinical relevance .
Background and Aims Ezetimibe reduces plasma low-density lipoprotein cholesterol ( LDL-C ) levels by up to 20 % .
However , its effect on plasma lipoprotein(a ) [ Lp(a ) ] concentrations in patients with primary hypercholesterolemia has not been defined .
Objective Therefore , we performed a systematic review and meta- analysis to assess this effect based on the available r and omized controlled trials ( RCTs ) .
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
AIMS To evaluate the efficacy and safety of ezetimibe 10 mg administered with pravastatin in patients with primary hypercholesterolemia . METHODS AND RESULTS After dietary stabilization , 2 - 12 week screening/washout period , and 4-week , single-blind , placebo lead-in period , 538 patients with baseline LDL-C > or = 3.8 to < or = 6.5 mmol/l and TG < or = 4.0 mmol/l were r and omized to one of eight possible treatments administered daily for 12 weeks : ezetimibe 10 mg ; pravastatin 10 , 20 , or 40 mg ; ezetimibe 10 mg plus pravastatin 10 , 20 , or 40 mg ; or placebo . The primary efficacy endpoint was percent reduction in LDL-C from baseline to study endpoint for ezetimibe 10 mg plus pravastatin ( pooled doses ) compared to pravastatin alone ( pooled doses ) and ezetimibe alone . The combined use of ezetimibe and pravastatin result ed in significant incremental reductions in LDL-C and TG compared to pooled pravastatin alone ( p<0.01 ) . Coadministration therapy reduced LDL-C by 34 - 41 % , TG by 21 - 23 % , and increased HDL-C by 7.8 - 8.4 % , depending on the dose of pravastatin . The combined regimen was well tolerated , with a safety profile similar to pravastatin alone and placebo . CONCLUSIONS When coadministered with pravastatin , ezetimibe provided significant incremental reductions in LDL-C and TG and was well tolerated with a safety profile similar to pravastatin alone
Conclusions Ezetimibe monotherapy ( 10 mg/day ) showed a small ( 7.06 % ) but statistically significant reduction in the plasma levels of Lp(a ) in patients with primary hypercholesterolemia .
According to current literature , this magnitude of reduction seems to have no clinical relevance .
Background and Aims Ezetimibe reduces plasma low-density lipoprotein cholesterol ( LDL-C ) levels by up to 20 % .
However , its effect on plasma lipoprotein(a ) [ Lp(a ) ] concentrations in patients with primary hypercholesterolemia has not been defined .
Objective Therefore , we performed a systematic review and meta- analysis to assess this effect based on the available r and omized controlled trials ( RCTs ) .